1 |
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis |
|
| | Ruben Mujica-Mota,Jo Varley-Campbell,Irina Tikhonova,Chris Cooper,Ed Griffin,Marcela Haasova,Jaime Peters,Stefano Lucherini,Juan Talens-Bou,Linda Long,David Sherriff,Mark Napier,John Ramage,Martin Hoyle | | | Health Technology Assessment. 2018; 22(49): 1 | | | [Pubmed] [Google Scholar] [DOI] | |
|